WAM
CRVS icon

Wealthspire Advisors (Maryland)’s Corvus Pharmaceuticals CRVS Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-365
Closed -$1K – 798
2019
Q1 		$1K Buy
+365
New +$1.54K ﹤0.01% 2314

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s CRVS Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Corvus Pharmaceuticals (CRVS) in Q2 2019, closing a stake of 365 shares — an estimated $1K sold.

Wealthspire Advisors (Maryland) first reported a position in CRVS in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 45 funds tracked by Wall St. Rank hold CRVS as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Corvus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 365 Corvus Pharmaceuticals shares in Q2 2019, an estimated $1K.
  • Wealthspire Advisors (Maryland) first reported a position in Corvus Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s Corvus Pharmaceuticals position peaked at $1K in Q1 2019.
  • 45 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.